Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study aims to conduct the first double-blind randomized trial comparing spironolactone and doxycycline for female acne treatment, with the goal of establishing spironolactone as a potentially superior alternative, especially given concerns about antibiotic resistance.

This chapter explores the promising use of low-power laser irradiation for post-hysterectomy reconstructive care, emphasizing enhancements like a flexible fiber optic module, to potentially improve genitourinary rehabilitation in cervical cancer patients.

The document explains how to determine your tax bracket and the effects of income changes on taxes.

This thesis explored the relationship between wholesale and retail prescription drug prices and concluded that unexpected negative mark-ups and inaccurate wholesale price comparisons suggest further investigation is needed.

This paper argues that the price difference between Proscar and Propecia represents price discrimination based on treatment indications despite both containing the same active ingredient, finasteride.

This article examines the pricing differences between Proscar and Propecia, concluding that this represents price discrimination for varying uses of the finasteride compound.

This article reviews the historical development and challenges of highway construction worldwide, highlighting key milestones from Italy's 1924 autobahn to China's leading pace in the 21st century, and reports no new results.

This study found that in Arabidopsis seedlings, tonoplast intrinsic proteins are targeted to the vacuole via at least two pathways, including pathways with differing sensitivity to a chemical inhibitor that affect root hair growth and PIN2 targeting.

This review explores factors influencing export potential, including resource availability, technological innovation, and labor efficiency, but provides no new empirical results.

This study found that big chain pharmacies in Pennsylvania charged significantly higher prices for generic BPH medications compared to independent pharmacies, which had more regional price variation.

This article reviews the conflicting approaches to patentability of dosage regimen inventions under Chinese law and reports no resolution on which position Chinese courts will adopt.

In this review, the authors examined the potential benefits of using wood tar in dermatology and cosmetics in Sub-Saharan Africa, based on its historical application in skin care and its worldwide usage.

This abstract reports no new research findings and instead provides information about the JAMA website features and usage terms.

In this study, researchers found that in Germany, orphan drugs with a phase III study and no comparable treatments available tend to receive higher HTA scores. There was no significant correlation between HTA scores and orphan drug prices or discount rates.

This study found that adjuvant docetaxel chemotherapy is linked to higher rates of dissatisfaction and chronic alopecia compared to paclitaxel chemotherapy, suggesting these outcomes should be discussed with patients before using docetaxel regimens.

This study found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg for treating severe alopecia areata at Weeks 24 and 52, potentially influencing reimbursement decisions.

This study examined the market trends for biologics that have lost patent exclusivity and predicted that drugs like adalimumab, once facing competition, could see price reductions and decreased market share, although the impact on accessibility and total patient use remains unclear.

This review discusses the legal status of patents for treatment and dosage regimes under the Patents Act 1977 and EPC 2000, highlighting ongoing uncertainties in their availability.

This study observed that tributyltin pollution induces imposex, reduces reproductive success, and leads to population decline in Ocinebrina aciculata, highlighting its sensitivity compared to other prosobranch species.

Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.

This study found that the proposed LC-MS/MS method accurately quantified the drug content in split tablets of finasteride and terbinafine, revealing significant variability and suggesting that non-scored tablets should not be split.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

The researchers reported that dPGS-PCL as a carrier improved the penetration of tofacitinib in an ex-vivo human skin model compared to free tofacitinib, but did not show significant differences in inhibiting IL-6 and IL-8 during short incubation.

This study reported that ZSYY001, a nanoparticle formulation of polymeric micellar paclitaxel, showed promising antitumor activity and was safe and well-tolerated in preclinical models and a phase I trial, without acute hypersensitivity reactions at doses up to 390 mg/m².

This review examines dermatological side effects of taxane chemotherapy reported in past studies and highlights the necessity for identifying and managing these conditions to maintain cancer patients' quality of life; it presents no new clinical results.

This study estimates that adding baricitinib to a commercial formulary for treating severe alopecia areata would slightly increase the budget by $1,383,345 over five years, with minimal impact per member per month.

In this study, FITC-labeled BSA nanocarriers delivered a model drug deeper into porcine ear skin hair follicles than the carriers themselves, as shown by confocal microscopy.

This court decision found that an Australian trader's use of an overseas competitor's trademark was not considered an infringement under Australian law.